Acreage Holdings, Inc.

The stock remains in a deep long-term downtrend, trading well below its 200-day average of 0.2846 and its 50-day average of 0.1598. The share price is still far from the 52-week high of 0.68, with the tape showing a low-priced, volatile recovery attempt rather than a confirmed trend reversal.

Street sentiment is mildly constructive but thin, with a Buy consensus split against one Hold and no Sell ratings. The average target of 0.4 sits well above the last close, but there have been no recent rating changes to reinforce a stronger re-rating.

Expect a difficult comparison: the company has missed EPS estimates in every reported quarter in the recent streak, with a 0/7 beat rate. Next-year EPS is modeled at -0.03 versus -0.85 for 2024, so shareholders should watch whether losses narrow and revenue stabilizes after a 32.9% YoY decline.

No discretionary insider buying or selling stands out. Recent activity is dominated by award and vesting-related grants to executives and directors, which reads as compensation flow rather than a conviction signal.

Profitability remains weak, with ROE at -135.6% and EPS TTM at -0.85. Gross margin is 49.5%, but revenue fell 32.9% year over year and the balance sheet carries $232.8 million of debt against $13.6 million of cash, leaving a heavy net debt load.

As a cannabis operator in healthcare, Acreage sits in a challenged niche with limited scale and persistent losses. The stock trades at a very low absolute valuation, with a market cap of about $4.9 million and a target price of 0.4 implying upside if execution improves.